CardioNet Awarded its 15th U.S. Patent

Newest Patent for Biological Signal Management
CONSHOHOCKEN, Pa.--(Business Wire)--
CardioNet, Inc. (NASDAQ: BEAT) announced today that the U.S. Patent and
Trademark office has granted patent number 7,587,237 ("Biological Signal
Management") to CardioNet. The patent includes certain systems and techniques
utilized by the Company`s Mobile Cardiac Outpatient Telemetry (MCOT) system that
automatically processes complex physiological information to make it useful for
clinical decisions. This is the 15th U.S. Patent that has been issued to
CardioNet.

Randy Thurman, CardioNet Chairman, President and CEO, commented, "A key to
success in delivering wireless medicine is rooted in our ability to distill the
wide variety of information collected from sensors on the body and make that
data useful for clinicians or other healthcare providers. With MCOT, we provide
electrocardiogram and trended heart rate data to physicians in order for them to
make clinically relevant decisions. The issuance of this patent demonstrates our
continued focus on innovation for applications in wireless medicine.
Establishing and defending our extensive patent portfolio is key to our
long-term strategy. This newly issued patent reinforces CardioNet`s position as
the pioneer and technology leader in mobile cardiac outpatient telemetry."

The issued patent abstract states: Systems and techniques for managing
biological signals. In one implementation, a method includes receiving a cardiac
biological signal that includes information describing events, determining a
merit of each event based on one or more of a severity of a cardiac condition
associated with the event and a quality of the event, and handling a subset of
the events that meet a merit criterion. The subset can be handled for medical
purposes.

About CardioNet

CardioNet is the leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely clinical
information regarding an individual's health. CardioNet's initial efforts are
focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm
disorders, with a solution that it markets as Mobile Cardiac Outpatient
Telemetry (MCOT). More information can be found at http://www.cardionet.com.

Forward Looking Statements

This press release includes certain forward-looking statements within the
meaning of the "Safe Harbor" provisions of the Private Securities Litigation
Reform Act of 1995 regarding, among other things, our growth prospects, the
prospects for our products and our confidence in the Company's future. These
statements may be identified by words such as "expect," "anticipate,"
"estimate," "intend," "plan," "believe," "promises" and other words and terms of
similar meaning. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including important
factors that could delay, divert, or change any of them, and could cause actual
outcomes and results to differ materially from current expectations. These
factors include, among other things, the success of our sales and marketing
initiatives, our ability to attract and retain talented executive management and
sales personnel, our ability to identify acquisition candidates, acquire them on
attractive terms and integrate their operations into our business, the
commercialization of new products, market factors, internal research and
development initiatives, partnered research and development initiatives,
competitive product development, changes in governmental regulations and
legislation, changes to reimbursement levels for our products, the continued
consolidation of payors, acceptance of our new products and services and patent
protection and litigation. For further details and a discussion of these and
other risks and uncertainties, please see our public filings with the Securities
and Exchange Commission, including our latest periodic reports on Form 10-K and
10-Q. We undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.

CardioNet, Inc.
Marty Galvan, 800-908-7103
Investor Relations
investorrelations@cardionet.com

Copyright Business Wire 2009